T. Rowe Price Associates’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
|
|||||
|
2025
Q1 | $43K | Buy |
|
|||||
|
2024
Q4 | $57K | Sell |
|
|||||
|
2024
Q3 | $184K | Hold |
|
|||||
|
2024
Q2 | $197K | Buy |
|
|||||
|
2024
Q1 | $253K | Buy |
|
|||||
|
2023
Q4 | $155K | Hold |
|
|||||
|
2023
Q3 | $110K | Sell |
|
|||||
|
2023
Q2 | $249K | Sell |
|
|||||
|
2023
Q1 | $381K | Sell |
|
|||||
|
2022
Q4 | $371K | Buy |
|
|||||
|
2022
Q3 | $464K | Sell |
|
|||||
|
2022
Q2 | $367K | Buy |
|
|||||
|
2022
Q1 | $322K | Buy |
|
|||||
|
2021
Q4 | $566K | Buy |
|
|||||
|
2021
Q3 | $623K | Hold |
|
|||||
|
2021
Q2 | $595K | Buy |
|
|||||
|
2021
Q1 | $604K | Sell |
|
|||||
|
2020
Q4 | $616K | Sell |
|
|||||
|
2020
Q3 | $486K | Hold |
|
|||||
|
2020
Q2 | $673K | Buy |
|
|||||
|
2020
Q1 | $446K | Buy |
|
|||||
|
2019
Q4 | $803K | Buy |
|
|||||
|
2019
Q3 | $186K | Buy |
|
|||||
|
2019
Q2 | $388K | Buy |
|
|||||
|
2019
Q1 | $193K | Buy |
|
|||||
|
2018
Q4 | $225K | Buy |
|
|||||
|
2018
Q3 | $357K | Sell |
|
|||||
|
2018
Q2 | $403K | Buy |
|
|||||
|
2018
Q1 | $287K | Buy |
|
|||||
|
2017
Q4 | $328K | Sell |
|
|||||
|
2017
Q3 | $660K | Buy |
|
|||||
|
2017
Q2 | $545K | Hold |
|
|||||
|
2017
Q1 | $475K | Buy |
|
|||||
|
2016
Q4 | $458K | Hold |
|
|||||
|
2016
Q3 | $598K | Sell |
|
|||||
|
2016
Q2 | $728K | Buy |
|
|||||
|
2016
Q1 | $587K | Buy |
|
|||||
|
2015
Q4 | $319K | Sell |
|
|||||
|
2015
Q3 | $319K | Buy |
|
|||||
|
2015
Q2 | $192K | Buy |
|
|||||
|
2015
Q1 | $81K | Sell |
|
|||||
|
2014
Q4 | $5.53M | Sell |
|
|||||
|
2014
Q3 | $8.67M | Buy |
|
|||||
|
2014
Q2 | $9.86M | Sell |
|
|||||
|
2014
Q1 | $11.2M | Sell |
|
|||||
|
2013
Q4 | $11.7M | Sell |
|
|||||
|
2013
Q3 | $32.8M | Sell |
|
|||||
|
2013
Q2 | $31.3M | Buy |
|